CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
Stock Information for Cel-Sci Corporation
Loading
Please wait while we load your information from QuoteMedia.